Susan Bowden, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3s611 Finley Rd, Sugar Grove, IL 60554 Phone: 815-762-1198 |
Mrs. Aimee L. Streicher, MA CCC SLP L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 236 Berkshire Ln, Sugar Grove, IL 60554 Phone: 630-605-9391 Fax: 630-466-3735 |
Gold Star Speech Therapy, P.c. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 236 Berkshire Ln, Sugar Grove, IL 60554 Phone: 630-605-9391 Fax: 630-466-3735 |
Iris Miriam Espinoza Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 58 W Park Ave, Sugar Grove, IL 60554 Phone: 331-227-4500 |
Violet J Gronberg Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 263 Chatsworth Ave, Sugar Grove, IL 60554 Phone: 630-466-5389 |
Miss Emily Osborn Peck, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 311 Mallard Ln, Sugar Grove, IL 60554 Phone: 630-721-6501 |
News Archive
The discomfort caused by esophageal (non-cardiac) chest pain is often severe, driving many patients to emergency rooms and physicians' offices despite the fact that the ailment has no definable pathology.
The Department of Veterans Affairs today announced a new Radiation Oncology Practice Assessment (ROPA) program to leverage recent advances in information technology to improve radiation therapy cancer care for our nation's Veterans.
Lawmakers in the state House could as early as Wednesday follow the example of their Senate counterparts to override Ark. Gov. Mike Beebe's veto of a bill that would ban most abortions in that state after 12 weeks of pregnancy. If it becomes law, it will become one of the most restrictive laws on abortion in the nation.
Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.
› Verified 4 days ago